Device drastically improves Barrett's esophagus, esophageal dysplasia detection

Listen
Text
  • Small
  • Medium
  • Large

A study, published in United European Gastroenterology Journal, found CDx Diagnostics Wats3D increased Barrett's esophagus and esophageal dysplasia detection by more than 80 percent.

Researchers conducted a multicenter trial at 25 community-based gastrointestinal centers across the U.S., testing 4,203 patients for esophageal disease.

Wats3D increased detection of Barrett's esophagus by 83 percent and improved the detection of dysplasia by 88 percent.

Researchers said the sampling error can be improved through the use of an adjunctive technique.

The data supports previous findings showing Wats3D effectively increased Barrett's esophagus detection rate.

CDx Diagnostics Founder and CEO Mark Rutenberg said, "Without Wats3D, gastroenterologists are forced to rely on chance, hoping that one of their small random forceps biopsies will happen to land on a highly focal area of precancer that may exist in their patient's esophagus. Now that we can more easily treat esophageal precancer through endoscopic ablation, the remaining obstacle to preventing the most rapidly growing cancer in the US is to more reliably identify those GERD and Barrett's patients with these still harmless but precancerous changes so that we can treat them in time to prevent their progression to adenocarcinoma."

Wats3D allows physicians to rapidly collect a sample of a patient's esophagus area. That sample is combined with 3-D imaging and expert cytopathology to detect precancerous cells.

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast